In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...